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Abstract
To identify new candidate therapeutic targets for Glioblastoma multiforme (GBM), we combined
functional genetics and GBM network modeling to identify kinases required for the growth of
patient-derived brain tumor initiating cells (BTICs), but which are dispensable to proliferating
human neural stem cells (NSCs). This approach yielded BUB1B/BUBR1, a critical mitotic spindle
checkpoint player, as the top scoring GBM-lethal kinase. Knockdown of BUB1B inhibited
expansion of BTIC isolates, both in vitro and in vivo, without affecting proliferation of NSCs or
astrocytes. Mechanistic studies revealed that BUB1B’s GLEBs domain activity is required to
suppress lethal kinetochore-microtubule (KT-MT) attachment defects in GBM isolates and
genetically transformed cells with altered sister KT dynamics, which likely favor KT-MT
instability. These results indicate that GBM tumors have added requirement for BUB1B to
suppress lethal consequences of altered KT function. They further suggest that sister KT
measurements may predict cancer-specific sensitivity to BUB1B inhibition and perhaps other
mitotic targets that affect KT-MT stability.
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most aggressive and common form of brain cancer
in adults (1). There are currently no effective therapies for GBM. Even with standard of care
treatments, such as surgery, radiation, and chemotherapy, ~90% of adult patients die within
2 years of diagnosis (2). Both adult and pediatric brain tumors appear to be hierarchically
organized suggestive of a cancer stem cell origin (3–6). Consistent with this notion, brain
tumor-initiating cells (BTICs) have recently been isolated that retain the development
potential and specific genetic alterations found in the patient’s tumor (3, 4, 7, 8). When
implanted into the cortex of rodents, BTICs give rise to GBM-like tumors with patient-
specific molecular signatures and histological features (5–8). Expression of neural
progenitor molecular networks may contribute to the aggressive behavior of GBM tumors
through enhancing self-renewal or developmental programs (9), DNA repair pathways (10),
angiogenesis (11), and/or invasiveness (12). Given the likelihood of BTIC-driven
maintenance and spread of GBM, effective cell-based therapies will likely have to target the
stem cell.
Recently, a new method for deriving and maintaining BTICs was developed in which adult
BTICs can be isolated and grown in serum-free, defined monolayer culture (7, 8). By this
method BTICs can retain tumor-initiating potential and tumor-specific genetic and
epigenetic signatures over extended outgrowth periods (13). Here, we sought to take
advantage of this BTIC culture system to find evidence for the cancer-lethal hypothesis: that
transformed cells harbor novel molecular vulnerabilities compared to “normal” cells as a
direct consequence of cancer-causing genetic alterations (14). Although multiple studies
have addressed the question of cancer lethality in serum-derived cell lines (15, 16), there
remain lingering questions of applicability to human cancers, since serum-derived lines may
not faithfully represent the primary cancer (7).
By combining the results of shRNA kinome screens in BTICs and NSCs for genes required
for progenitor expansion with a GBM bionetwork created from patient molecular signatures,
we identified BUB1B, a critical mitotic checkpoint kinase (17), as the top GBM-specific hit.
Our results suggest that GBM tumors and genetically transformed cells have added
requirement for BUB1B to suppress lethal consequences of altered KT function.
Importantly, these studies demonstrate that non-transformed cells do not require BUB1B/
BubR1 for chromosome alignment, nor do they require the GLEBs domain to maintain the
spindle assembly checkpoint. They further suggest that altered KT conformations, apparent
in GBM and genetically transformed cells, may predict cancer-specific sensitivity to
BUB1B inhibition and perhaps other mitotic targets that affect KT-MT stability.
RESULTS
An RNAi kinome screen for genes differentially required for BTIC expansion
To discover candidate therapeutic targets for GBM, we performed an shRNA screen
targeting 713 human kinases to identify gene activities required for in vitro expansion of
BTICs. To enrich for BTIC-specific hits, a parallel screen was conducted in human fetal
NSC-CB660 cells (Fig. 1A) (18). NSCs share molecular and phenotypic features with
BTICs, including: identical isolation and growth in serum-free conditions, similar doubling
times, overlapping expression profiles, and similar developmental potential (18). However,
they retain a normal karyotype and are not tumorigenic (18), and, thereby, represent ideal
controls for BTICs.
This screening approach (see Methods for details) revealed ~48 candidate kinase targets
with shRNAs underrepresented in BTICs relative to NSCs (Table S1). To prioritize these
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hits, we examined whether hits could be parsed into distinct pathways and/or complexes
using protein-protein interaction networks (19). By this analysis, most hits were connected
in a single, large subnetwork, enriched for 248 GO biological processes (multiple testing
adjusted p-value<0.01), such as protein kinase cascade (p-value= 5.57881e-085) and protein
amino acid phosphorylation (p-value=1.10068e-082). This lack of specific biological
processes likely reflected the fact that these kinases are well studied and involved in many
biological processes and, thus, did not provide any useful information for prioritizing of
candidate hits.
As an alternative strategy, we examined the occurrence of screen hits in GBM specific
regulatory network, constructed de novo from over 421 TCGA GBM tumor samples (20) by
integrating gene expression and DNA copy number variation data (21, 22) (Supplementary
Information). By this analysis, 37 of 48 shRNA candidate hits appeared as nodes in the
GBM network. Examination of subnetworks in the GBM network, revealed 15 biological
processes significantly enriched (5 cell cycle related, 9 general phosphorylation related),
including the M phase of mitotic cell cycle (p-value=1.64e-5). The largest GBM-specific
subnetwork contained four screen hits, including AURKB, BUB1B, MELK, and PLK1 (Fig.
1B). Based on key driver node analysis (23), BUB1B scored as the top ranked screen hit
(Fig. 1C).
To control for GBM network comparisons, we also examined screen hits in a normal brain
network constructed from 160 non-dementia human prefrontal cortex samples. Only 20 of
the 48 candidate hits appeared in the normal brain network, and produced smaller
subnetworks enriched for general phosphorylation related GO biological processes (data not
shown). Although BUB1B appeared in this network, it was connected to only one gene and
had no down nodes (Fig. 1B), and, thus, was not a key driver node.
BUB1B is differentially required for BTIC expansion
Retests of AURKB, BUB1B, MELK, and PLK1 revealed that BUB1B inhibition gave the
largest differential effect on BTICs from multiple GBM isolates, including common
developmental subtypes (24), without observable toxicity in proliferating NSCs or astrocytes
(Figs. 1A–D). In these studies, shRNA expressing cells were subjected to short- and long-
term out growth assays (Fig. 2D and Supplementary Fig. S1A–B). Knockdown of KIF11
was used as a positive control. KIF11 encodes a microtubule motor protein required for
mitotic progression in proliferating mammalian cells (13). During short and long term
outgrowth shKIF11 blocked the growth of BTICs, NSCs, and astrocytes. Since shKIF11
only inhibits cycling cells entering mitosis, shKIF11-dependent growth inhibition indicates
similar division rates for various cells used and that they have comparable RNAi pathway
activity. However, BUB1B knockdown only triggered significant growth inhibition in BTIC
lines (Figs. 2A & D). During longer-term outgrowth shBUB1B inhibited the growth of
SSEA1+ BTIC subpopulations, which are enriched for tumor initiating cell activity (25)
(Supplementary Fig. S1C–D). BUB1B knockdown was also deleterious to BTIC tumor
sphere formation, which may reflect tumor initiating cell activity (5, 6), in both BTICs and
primary tumor samples (Fig. 2E). However, knockdown did not profoundly alter expression
of SSEA1 or other progenitor markers, including SOX2 and NESTIN, or neural lineage
markers, including GFAP and TUJ1 (data not shown).
By contrast, PLK1 knockdown had a partial effect; MELK knockdown had no effect; and
inhibition of AURKB was equally toxic to BTICs and NSCs (Supplementary Fig. S2A–C).
Based on these results, we further pursued BUB1B as a candidate BTIC-lethal gene.
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BUB1B is overexpressed in GBM isolates and its checkpoint activity is compromised by
shBUB1B in both BTICs and NSCs
BUB1B encodes a highly conserved BUB1-like kinase, BubR1, whose activity is essential
for mitotic spindle checkpoint signaling (17). The mitotic spindle checkpoint monitors the
attachment of kinetochores to the plus ends of spindle microtubules and prevents anaphase
onset until chromosomes are aligned and kinetochores are under tension at the metaphase
plate (17). Due to its role in maintaining chromosome stability, mitotic spindle checkpoint
activity has been touted as a mechanism for tumor suppression (17, 26). In rare instances
partial loss of function mutations in checkpoint genes have been reported for certain cancers
(26). However, many late-stage cancers, including glioma, exhibit high BUB1B expression
(27, 28), suggestive of hyperactivity.
To begin to reconcile these observations with our results, we analyzed BUB1B expression
patterns and activity in BTICs and NSCs. We observed that BUB1B and other spindle
checkpoint genes were up regulated in BTIC isolates and also Ras-transformed astrocytes as
judged by mRNA and protein abundance (Supplementary Fig. S3A–C). Moreover, both
BTICs and NSCs had normal mitotic spindle arrest responses after taxol treatment, which
were abrogated by BUB1B knockdown (Supplementary Fig. S4A–C). Thus, BUB1B
knockdown achieves a similar level of suppression of BUB1B mRNA, protein, and activity
in both BTICs and NSCs. The results suggest that BUB1B knockdown produces a
hypomorphic state to which BTICs, but not NSCs or astrocytes, are sensitive. Below we
provide further evidence to support this conclusion, by addressing BUB1B’s essential and
non-essential functions in BTICs, transformed, and untransformed cells.
Shortened inter-kinetochore distances are indicative of sensitivity to shBUB1B in BTICs
and genetically transformed cells
One possible explanation for BTIC’s observed sensitivity to hypomorphic BUB1B activity
is that KT-MT dynamics could be altered to favor MT detachment. In order to properly
segregate chromosomes during mitosis, stable attachments must occur between the “plus”
end of mitotic spindle MTs and KTs, which are formed at centromeres of each sister
chromatid as cells enter mitosis (29). Early in mitosis, KT-MT attachments are unstable and
dynamic, allowing chromosomes to be towed toward MT plus ends during congression and
improperly attached chromosomes to be released and re-attached to spindle MTs until they
are bi-oriented and under tension (19, 29). The distance between KTs on sister chromatids
can range from ~0.6 μm in prophase to >1 μm in metaphase, when sister KTs achieve stable
MT attachment and are pulled toward opposing spindle poles (Fig. 3A) (30). In the
prevailing model, this KT movement prevents outer kinetochore proteins from being
phosphorylated by Aurora B kinase, which promotes KT-MT detachment (e.g., for error
correction), by physically removing them from centromere-embedded Aurora B activity
(29).
To examine KT-MT dynamics, we first investigated the possibility that KT dynamics may
be altered in GBM cells. To this end, we measured inter-kinetochore distance (IKD): the
maximum distance achieved between sister KTs when stable end-on MT attachment has
occurred (31). We first measured IKDs for shBUB1B insensitive NSCs (CB660) and two
shBUB1B sensitive BTIC isolates (G166 and 0131). The results were surprising. We found
that IKDs were significantly shorter in both BTIC isolates (1.23 μm for CB660 vs. 1.13 μm
for G166 and 1.09 μm for 0131) (Figs. 3B & C). Thus, BTICs IKDs were short by 100–140
nm, or 50–70 nm for each sister KT. This represents a significant change, since, for
example, the outer kinetochore protein Hec1 moves ~40 nm toward the spindle pole as KTs
come under tension (32, 33).
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Next, we examined IKDs in two GBM patient isolates, 0827 and 1502, that we had observed
were completely insensitive to shBUB1B. These isolates were insensitive despite having
similar knockdown efficiencies to shBUB1B sensitive lines and among the fastest doubling
times and tumor initiation rates (data not shown). Measuring IKDs in these cells revealed
that they were indistinguishable from NSCs (1.23 μm), suggesting the possibility that IKDs
may predict BUB1B sensitivity (Figs. 3B & C).
To further examine this possibility, we tested a hypothesis: that shortened IKDs and added
BUB1B requirement arise as a result of oncogenic transformation and, specifically,
oncogenic signaling. It was recently shown that expression of activated Ras oncogene can
lead to mitotic stress and induce chromosome instability in mammalian cell, through an as
yet undefined mechanism (16). Thereby, we examined IKDs in p53−/− mouse embryo
fibroblasts with or without RasV12 expression. In p53−/− control MEFs, IKDs averaged
1.25 μm similar to NSCs and 827 cells. Surprisingly, RasV12 expression converted long
IKDs to short, averaging 1.13 μm, indistinguishable from G166 and 0131 cells (Fig. 3D).
Moreover, RasV12 transformation also converted MEFs from being resistant to BUB1B
inhibition to being profoundly sensitive, which was also true for human astrocytes (Fig. 3D)
as well (both experiments are presented below in Fig. 5 & Supplementary Figs. S8A–C).
Importantly, all of the IKD measurements for BTICs, NSCs, and MEFs IKDs were scored
blindly to avoid experimenter bias.
Since most BUB1B/BubR1 experimentation has been performed in HeLa cells, which are
derived from a cervical carcinoma (16), we next measured IKDs in these cells. As a control,
we used immortalized retinal pigment epithelial (RPE-1) cells, which are untransformed.
Hela cells showed IKDs similar to other BUB1B sensitive cells (1.11 μm), while RPE cells
showed long IKD similar to insensitive cells (1.22 μm). Repeating the pattern above
BUB1B knockdown only affected chromosome dynamics in Hela cells (detailed below).
These results suggest: 1) that IKDs occur in discrete intervals: long (~1.24 μm) and short
(~1.12 μm); 2) that short IKDs predict sensitivity to BUB1B inhibition; and 3) that RasV12
transformation is sufficient to induce short IKDs and sensitivity to BUB1B.
GBM isolates with short inter-kinetochore distances require BUB1B to suppress severe
KT-MT attachment defects
We next wished to determine whether BTICs with short IKDs have altered KT-MT
dynamics that favor detachment. To this end, we used a metaphase chromosome alignment
assay, in which KT-MT attachment defects are visualized as misaligned chromosomes
during metaphase arrest induced by proteasome inhibition (34). By this assay, knockdown of
BUB1B resulted in dramatic chromosome alignment defects only in BTICs with short IKDs,
but did not affect alignment in NSCs, 0827 cells (Figs. 4A & 4B; Supplementary Fig. S5A)
or astrocytes (see below). The alignment defects in G166 cells were accompanied by
profound loss of KT-MT attachment, as indicated by lack of co-localization KTs with cold
resistant MTs (Supplementary Fig. S5B). Moreover, examination of phospho-Ser44-Hec1/
Ndc80 at KTs revealed that after BUB1B knockdown, G166s retain Ser44-P (35)
(Supplementary Fig. S5C). This phosphorylation is dependent upon centromere-embedded
Aurora B kinase activity, and has a KT-MT destabilizing effect (29). These results suggest
that cells with short IKDs have KT-MT attachment defects, which BUB1B is required to
suppress.
Consistent with this notion, G166 cells also displayed overt differences in chromosome
dynamics during mitosis, with significantly more lagging chromosomes in anaphase
compared to NSCs (Fig. 4C). BUB1B knockdown dramatically exacerbated these defects
(Fig. 4D). In control experiments in NSCs, shBUB1B did not affect lagging chromosome
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frequency or karyotype after extended outgrowth (Fig. 4C; Supplementary Fig. S5D), again
suggesting that cells with long IKDs do not utilize BUB1B in the same way.
Genetic dissection of added requirement of BUB1B in RasV12-expressing fibroblasts and
BTIC cells
BUB1B has multiple functional domains that have been implicated in mitotic checkpoint
control, mitotic timing, and stable kinetochore-microtubule attachment (17, 29). These
include: N- and C-terminal KEN box domains required for Cdc20 binding and APC
inhibition (36–38); a C-terminal kinase domain involved in checkpoint control (39, 40); and
a GLEBS-like motif necessary for KT localization during mitosis (39, 41) (Fig. 5A). While
BUB1B is essential for mammalian development (42), its essential function is contained
solely within the N-terminal KEN box (36), which enables Bub1b to act as a pseudo-
substrate inhibitor of APC/CCdc20 during G2 and pre-anaphase mitosis, preventing a
precocious anaphase (36).
The above results suggested that BTICs with short IKDs have added requirement for
BUB1B that helps facilitate KT-MT attachment. BUB1B’s GLEBS domain is necessary for
its KT localization, interaction with Bub3, and helps facilitate KT-MT attachment (39, 41).
Recently, Maulureanu et al (2009) demonstrated that this domain is non-essential for stable
end-on KT-MT attachment and viability in mouse embryo fibroblasts (MEFs). Their results,
however, were not consistent with previous work in HeLa cells that clearly demonstrated
that the GLEBs domain is essential for KT-MT attachment (43). Intriguingly, our data sets
inform these seemingly incompatible results with the following thesis: BUB1B’s GLEB
domain is required in cells with abnormal KT conformations (e.g., Helas) to suppress lethal
KT-MT instability. Furthermore, since our results above, demonstrate that RasV12
transformation can convert long IKDs to short, it would follow that oncogenic
transformation gives rise to added BUB1B requirement.
To directly address this notion, we next performed allelic complementation studies using
mouse Bub1b alleles (Fig. 5A) in mouse embryo fibroblasts (MEFs) harboring bi-allelic
deletion of Bub1b (36), which were also transformed by H-RasV12. For these experiments,
we used full-length mBub1b, the N-terminal deletion mutant and the E406K GLEB domain
mutant allele, which cannot bind to KTs. Expression of each allele was verified by western
blotting (Supplementary Fig. S6A–C). For non-transformed MEFs, the viability pattern was
the same as previously published (36): both FL and E406K alleles fully complemented
Bub1b−/− and only the N-terminal KEN box domain was required for Bub1b−/− cell growth
(Fig. 5B). However, after Ras-dependent transformation of these cells, the results changed
dramatically. The GLEBs domain became essential for viability, as evidenced by the
complete failure of the E406K allele to complement (Fig. 5B). RasV12 activity, however,
did not alter requirement N-terminal KEN box domain. These results demonstrate that
RasV12 transformation leads to profound requirement for BUB1B’s GLEBs domain
activity.
To further examine this result, we performed a similar set of complementation experiments
in BTIC-G166 cells, using mouse Bub1b alleles to complement knockdown of endogenous
human BUB1B. In this case, kinase defective and internal KEN box deletion alleles were
also included (Fig. 5C). Expression of each allele was confirmed by western blotting
(Supplementary Fig. S6A–B). Knockdown efficiency of endogenous BUB1B was also
shown to be unaffected by expression of mouse Bub1b (shBUB1B is not predicted to target
mouse Bub1b) (Supplementary Fig. S6C). As shown in Figure 5C, expression of full length
and KD2 mBub1b alleles achieved near-complete rescue of the viability defects of BUB1B
knockdown in G166 cells, indicating that the shBUB1B phenotype is due to on-target
silencing of BUB1B, and that BUB1B’s kinase activity is not required in BTICs. By contrast
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the ΔN and E406K alleles, failed to complement viability, behaving exactly as the vector
control, while ΔM showed a partial rescue (Fig. 5C). None of the alleles were able to
complement control KIF11 knockdown. Thus, these results phenocopy those observed in
RasV12-transformed MEFs.
To further investigate these results, we performed KT-MT attachment using chromosome
alignment assays as described above. All alleles showed complete or partial suppression of
alignment defects, except for E406K, which failed to complement (Figures 5D & 5E). This
demonstrates that BUB1B’s GLEBs domain is essential for both viability and stable-end on
attachment of MTs to KTs in BTICs with short IKDs.
Since BUB1B’s essential function is to prevent precocious anaphase through inhibiting
APCCdc20 activity, we also examined mitotic transit times in the same series of
complementation experiments. BUB1B knockdown causes significant reduction in transit
times in BTICs, which all alleles were able to complement, except for ΔN (ΔM was not
determined) (Supplementary Fig. S7). Since the E406K allele restored mitotic timing, but
not viability or KT-MT attachment, this would suggest that requirement for BUB1B-GLEBs
domain activity is distinct from BUB1B-dependent APC regulation.
To provide additional evidence for transformation dependent changes in BUB1B function in
human cells, we examined viability and KT-MT attachment requirements for BUB1B in
normal human astrocytes with and without expression of RasV12. Knockdown of BUB1B in
RasV12- NHA, but not NHA controls, resulted in loss of viability and severe KT-MT
defects (Supplementary Fig. S8A–B). These results were, again, consistent with the notion
that oncogenic transformation leads to added requirement for BUB1B to stabilize KT-MT
attachments. A similar pattern was observed in HeLa cells and non-transformed RPE cells.
~93% of HeLa cells treated with siBUB1B have severe KT-MT attatchment defects
(n>100), compared to only 17% for control; while KT-MT attachment was similar
regardless of siBUB1B treatment (n>150) (Supplementary Fig. S8C).
Several key conclusions can be drawn from these studies: 1) BUB1B is the relevant target of
shBUB1B in BTICs; 2) BUB1B’s kinase activity is dispensable for added BUB1B
requirement in BTICs; 3) promotion of KT-MT attachment, rather than restoration of BTIC-
mitotic delay/timing, is a key BTIC-lethality suppressing activity; 4) GBM cells differ in
their requirement for BUB1B’s GLEBS domain as compared to cells with long IKDs; and 5)
that oncogenic transformation drives added requirement for BUB1B’s GLEBs domain.
ShBUB1B inhibits BTIC-driven tumor formation
Lastly, to ensure that the above results are applicable to patient tumor formation, we
examined BUB1B requirement during BTIC tumor formation, for a BTIC line with short
IKDs. We performed two different assays. In the first, shRNA-GFP+ 0131 cells competed
against non-shRNA control 0131 cells at ~9:1 ratio (Fig. 6A) for injection into the cortex of
immunodeficient mice. The end point was relative representation of shBUB1B. After 4 or 7
weeks post-injection, control cells had dramatically outcompeted shBUB1B-GFP+ cells
(Fig. 6A). This was not simply due to inviability of injected cells at Day 0, since the most
shBUB1B-GFP+ cells in the injection bolus could attach to laminin-coated dishes. For the
second assay, survival was the end point for mice injected with either shControl or
shBUB1B expressing 0131 cells (Fig. 6B). This assay ended at 250 days post-injection when
90% of control mice had succumbed to tumors. During this time none of the shBUB1B-0131
mice died. These results suggest that knockdown of BUB1B is deleterious to GBM tumor
formation and that the in vivo tumor environment does not suppress requirement for
BUB1B.
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Discussion
Here we attempted to identify kinases differentially required for the expansion of GBM-
derived BTICs by combining a functional genetic approach with a GBM bionetwork derived
from patient sample molecular data sets (44). This approach produced BUB1B as the top-
scoring screen hit. Validation studies bore out this prediction: knockdown of BUB1B
differentially blocked expansion of 9 of 11 BTIC isolates examined, without effecting
growth of human NSCs and astrocytes, which are both candidate cell types of origin for
GBM (44).
BUB1B encodes a highly conserved BUB1-like kinase, BubR1, whose activity is essential
for mitotic spindle checkpoint signaling (17). The mitotic spindle checkpoint monitors the
attachment of kinetochores to the plus ends of spindle microtubules and prevents anaphase
onset until chromosomes are aligned and kinetochores are under tension at the metaphase
plate (17). To pursue the mechanism of BUB1B requirement in GBM cells, we tested a
hypothesis: that KT-MT dynamics are fundamentally altered in GBM cells to favor KT-MT
detachment, which BUB1B is required to suppress.
This hypothesis was supported by multiple observations (summarized in Fig. 7). First, in
examining sister KT dynamics at metaphase, we demonstrated that GBM and other cancer
cells sensitive to BUB1B inhibition have significantly shorter IKDs, indicating that KT
dynamics are dramatically altered. Second, in BTICs with short IKDs, BUB1B activity is
required to suppress lethal KT-MT instability and to directly or indirectly inhibit
centromere-embedded Aurora B activity on outer KT proteins. Third, expression of the
RasV12 oncogene is sufficient to induce the same changes in sister KTs observed in BTICs.
Fourth, RasV12 also triggered requirement for BUB1B’s GLEBs domain for both viability
and KT-MT attachment. Fifth, genetic dissection of BUB1B function in BTICs with short
IKDs revealed the same requirement for BUB1B’s GLEBs domain to suppress lethal KT-
MT instability.
These results support a model whereby oncogenic signaling alters KT regulation, resulting
in short IKDs and KT-MT instability. As a direct result, BUB1B’s GLEBs domain activity
becomes essential for KT-MT attachment. In the absence of GLEBs domain activity cells
with short IKD undergo mitotic catastrophe and are inviable (Fig. 7). Importantly, our
studies demonstrate that non-transformed cells do not require BUB1B/BubR1 for
chromosome alignment, nor do they require the GLEBs domain to maintain the spindle
assembly checkpoint or viability.
One key implication of this work is that short IKDs may be predictive of requirement for
BUB1B’s GLEBs domain and sensitivity to disruption of KT function in cancer cells. For
example, we have found patient GBM isolates (i.e., 0827, 1502) that are resistant to BUB1B
knockdown and have IKDs indistinguishable from untransformed cells. Thus, it is
conceivable that anti-cancer therapies targeting KT or mitotic checkpoint function (e.g., (45,
46)) would benefit from using IKDs as a biomarker or companion diagnostic. However,
additional studies are required to determine the extent to which IKDs are shorter in cancer
cells and also the mechanisms through which KT conformations become perturbed.
One possibility is that RTK-Ras signaling directly affects KT function. There is evidence
that Ras effector kinases Erk1/2 can directly phosphorylate the C-terminal domain of
CENPE, a key KT protein, which is predicted to decrease its MT binding ability (47, 48).
Intriguingly, we observed that in both BTIC-G166 and RasV12-transformed astrocytes,
which have short IKDs, there is significant up regulation of Erk1/2 activity in prophase and
mitosis (Supplementary Fig. S9). Thus, it is conceivable that inappropriate regulation of
RTK-Ras pathway in mitosis could directly effect KT-MT attachments and/or KT
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conformational states. Although RasV12-transformed astrocytes may not faithful
recapitulate the mutation spectra of GBM (only ~2% have mutant Ras activity (20)), the Ras
pathway is predicted inappropriately activated in the majority of GBM tumors (20) (e.g., by
NF1 mutation or RTK activity). Future work is required to examine the relationship between
Ras signaling and KT regulation.
Our results also shed light on a recent study that identified genes differentially required in
cancer cell lines overexpressing the activated KRAS oncogene (16). Their results suggest
that activated Ras oncogene activity triggers differential requirement for a PLK1-kinase-
associated mitotic network (16), which they proposed resulted from Ras-induced “mitotic
stress”. Our results suggest that these phenotypes likely result from KT-MT attachment
defects arising from KT conformational abnormalities.
Lastly, our studies also inform the use of large collection of cancer patient molecular
signatures. We used >300 GBM patient molecular signatures to create a Bayesian
bionetwork, which when combined with our functional genetic data, predicted BUB1B
inhibition to be differentially lethal for GBM cells. To our knowledge this is the first time a
bionetwork derived solely from patient data has been used to successfully predict a gene
activity specifically required for cancer cells. Intriguingly, integrating our BTIC kinome data
set into bionetwork for breast cancer also yielded BUB1B as the top scoring hit (J. Zhu,
personal communication), suggesting that our results should prove useful for other cancers.
In summary, our results suggest that GBM tumors and genetically transformed cells have
added requirement for BUB1B to suppress lethal consequences of altered KT function. They
further suggest that IKDs may predict cancer-specific sensitivity to BUB1B inhibition and
perhaps other mitotic targets that affect KT-MT stability.
METHODS
ShRNA Bar-code screens and array analysis
For shRNA screen and Bar-code array analysis cells were infected with a pool of lentiviral
shRNAs targeting 713 human kinases at a representation of ~1,000 fold (MOI<1). At day 3
post-infection an initial Day-0 sample was taken. The rest of the population was selected
with puromycin (Sigma) (2 μg/ml) to remove uninfected cells. Afterwards, cells were
propagated in culture for an additional 21 days and sampled for BC array analysis at 21
days. For each passage a minimal representation of 1000 fold was maintained. For each
corresponding sample, shRNA barcodes were PCR-recovered from genomic samples,
labeled with Cy5 or Cy3, and competitively hybridized to a microarray containing the
corresponding probes (Agilent Technologies). Replicate array results were analyzed using
the BioConductor package limma. The change in the relative abundance of each shRNA in
the library over time was measured using the normalized Cy3/Cy5 ratio of its probe signal.
Barcode probes depleted in the BTIC samples were considered candidate genes using the
following criteria: 1) adjusted p-value ≤ 0.05 and 2) |log2(ratio)| ≥ 0.585.
Cell culture
BTIC and NSC lines used in these studies have been previously published (7,8) and were
grown in N2B27 neural basal media (Stemcell Technologies) supplemented with EGF and
FGF-2 (20 ng/mL each) (Peprotech) on laminin (Sigma) coated polystyrene plates and
passaged according to Pollard (8). Immortalized neural stem cells, CX and VM (Millipore),
were maintained in ReNcell maintenance medium with EGF and FGF-2 (20 ng/mL each)
(Peprotech) and also grown on laminin coated tissue culture treated plates and passaged
according to Pollard (8). NHA (StemCell Technologies) and NHA-Ras cells (Russell Pieper,
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UCSF) were grown in astrocyte growth medium (Clonetics) according to the manufacturer’s
instructions and published protocols (49).
RNAi
ShRNAs were obtained from the RNAi Shared Resource (FHCRC) or Open Biosystems
(Huntsville, AL) in the pGIPZ lentiviral vector. Target sequences for shRNAs are as
follows: BUB1B, #1, CDS:1417, CCTACAAAGGAGACAACTA; BUB1B, #2, CDS:1547,
AGGAACAACCTCATTCTAA; and KIF11, CDS:571, AAGAGAGGAGTGATAATTA.
For virus production pGIPZ-shRNA plasmids were transfected into 293T cells along with
psPAX and pMD2.G packaging plasmid to produce lentivirus. ~24 hours after transfection,
neural stem cell expansion medium was added to replace original growth medium. Virus
was harvested 24 hours after medium change and stored at −80C. BTICs and NSCs were
infected at MOI<1 and selected with 2–4 μg of puromycin for 2–4 days.
RT-qPCR
Quantitect RT-qPCR primer sets and QuantiFast SYBR Green PCR Kits (Qiagen) were used
according to the manufacturer’s instructions with the ABI Prism 7900 sequence detection
system (Genomics Resource, FHCRC). Relative transcript abundance was analyzed using 2
ΔΔCt method. TRIZOL (Invitrogen) extraction was used to collect total RNA from cells.
Western Blot
Western Blots were carried out using standard laboratory practices, except that a modified
RIPA buffer was used for protein extraction (150 mM NaCl, 50 mM Tris, 2 mM MgCl2, .
1% SDS, .4% DOC, .4% Triton-X 100, 2 mM DTT, and complete protease inhibitors
(Roche)) followed by a 15 min digestion with 125U of Benzonase (Merck) at RT. The
following antibodies were used for detection: Bub1B (1:1000, Sigma), Actin (1:1000, Cell
Signaling) and cleaved Parp (1:1000, Cell Signaling). An Odyssey infrared imaging system
was used to visualize blots (Li-cor) following manufacture’s instruction.
Growth Assays
For short-term outgrowth assays, post-selection, shRNA transduced cells were harvested,
counted (Nucleocounter, NBS), and plated onto a 96-well plate. After 7 days under standard
growth conditions, cell proliferative rate was measured using Alamar blue reagent
(Invitrogen). For long-term outgrowth assays, post-selection, shRNA transduced cells were
mixed with non-transduced cells (9:1) and outgrown for 14–24 days using our standard
passaging protocol. The GFP+ fraction, which marks shRNA containing cells, of each
population was measured by FACS (BD LSR2 flow cytometer; FHCRC Shared Resources)
at 5–8 day intervals.
Spindle checkpoint arrest
For image-based assessment, cells were plated in a 96 well plate and then treated with
paciltaxol (Sigma) and nocodozole (Sigma) for various time points (6–18 hrs). After
treatment, cells were fixed with 2% paraformaldehyde for 30 minutes, permeabilized with
0.25% Triton X-100, and blocked in PBS containing 3% BSA and 5% goat serum. After 3
washes with PBS, cells were stained with MPM-2 (1:300, Millipore) at room temperature
for 1 hour. Next, cells were washed and incubated with Alexaflour-568 secondary antibody
(Invitrogen) and DAPI for 1 hour in dark. Staining was visualized by Nikon eclipse Ti
microscope. For FACS-based assessment, cells were then collected and fixed in 70%
ethanol for 1 hour at 4°C, then rinsed with ice-cold PBS+2% FCS, and stained with anti-
MPM-2 (1:300, Millipore), anti-mouse Alexafluor-568 (1:200, Invitrogen), and DAPI (1 μg/
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ml). Cells were washed, re-suspended in PBS and filtered. Mitotic index was measured by
BD LSR2 flow cytometer (FHCRC Shared Resources).
Mitotic transit time
NSC and BTIC cells were transduced with control and BUB1B hairpins, respectively. After
selection, cells were plated into a 96 well plate for time-lapse microscopy. During imaging,
the atmosphere was maintained at a temperature of 37°C and 5% CO2. Imaging was
performed using a Nikon Eclipse Ti microscope equipped with a live imaging system. Nikon
elements software was used to collect and process data. Images were captured at 5.3 minute
intervals for 16 hours.
Lagging chromosome assay
For one-step arrest in prometaphase, cells were treated overnight with the Eg5 kinesin
inhibitor monastrol (100 μM final concentration) overnight. DAPI staining was performed
to visualize abnormal anaphase frequency. Monastrol inhibits the mitotic kinesin Eg5/Kif11,
a motor protein required for spindle bipolarity, and specifically arrest cells in G2/M (26, 34).
Cells were washed and released into fresh media for 2 hours and then fixed (4% PF),
permeabilized, stained with DAPI, and visualized using a Nikon Eclipse E800 (Scientific
Imaging, FHCRC). >400 nuclei will be counted for each trial (n=5) and student’s t-test will
determine significance. For asynchronous populations, cells were additionally stained with
an MPM-2 antibody (Millipore), which marks mitotic cells, and counter stained with DAPI
(Sigma). Approximately one third of MPM-2 positive cells in asynchronous cultures where
in anaphase/telophase, while the other two thirds where in prometaphase or metaphase.
Chromosome alignment assays
For metaphase staining, cells were treated by 10 μM MG-132 (TOCRIS Bioscience) for 2
hours to arrest them at metaphase and then fixed for 20 min at room temperature with 4%
formaldehyde in PBS and 0.2% Triton X-100. For cold stable microtubules, cells were
incubated on ice for 15 min prior to fixation. After fixation, cells were blocked and stained
with α-tubulin (Sigma, DM1A; 1:1000) and CREST anti-serum (Immunovision; 1:1000) at
room temperature for 1 hour. Cells were washed and incubated with secondary antibody and
DAPI for 1 hour in the dark. Immunolabeled cells were imaged on a Deltavision RT
deconvolution microscope (Applied Precision Inc., Issaquah, WA). Optical sections were
acquired at 0.2 micron spacing with an Olympus 100x/1.4 NA UPLS Apo objective. 3-D
image stacks were deconvolved with Applied Precision’s proprietary software Softworx,
using a constrained iterative algorithm. Deconvolved 3-D data were loaded into the
visualization software Velocity (PerkinElmer, Waltham MA). The number of misaligned
microtubule-attached kinetochores was counted based on CREST staining on 3-D rendered
images, and confirmed by visual inspection of maximum intensity projections of whole
cells. Misaligned kinetochores were defined as those with normalized distance <0.2. At least
30 cells were analyzed for each RNAi experiment.
Xenotransplantation
131 BTIC cells were infected with pGIPZ-shRNA virus and selected for 3 days in
puromycin (2 μg/mL), such that >80% of cells were GFP+. Cells were then harvested using
Accutase (Sigma), counted, resuspended in an appropriate volume of culture media, and
kept on ice prior to immediate transplantation. NOD-scid IL2Rgammanull mice (Jackson
Labs #005557) were anesthetized by IP injection of 0.2 ml/10 grams 1.25% Avertin Solution
and kept at 37°C. A small bore hole was made in the skull using a hand drill with a
Meisinger #009 steel burr bit (Hager & Meisinger GmbH). 2×10^5 cells were slowly
injected by pipet into the right frontal cortex approximately 2 mm rostral to Bregma, 2 mm
Ding et al. Page 11
Cancer Discov. Author manuscript; available in PMC 2014 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
lateral and 3 mm deep through a 0.2–10 ul disposable sterile aerosol barrier tip (Fisher
Scientific #02-707-30). The burr hole was closed using SURGIFOAM (Johnson & Johnson)
and the skin rejoined using TISSUMEND II (Veterinary Product Laboratories, Phoenix AZ).
Brain Tumor Imaging
Seven weeks after initial transplantation mice were injected intravenously with 50 μl of 40
μM Chlorotoxin: Cy5.5 conjugate (50) 2 hours prior to sacrifice by carbon dioxide
inhalation. The brain and tumor were removed from the skull and imaged for Cy5.5 and
GFP fluorescence using the Xenogen IVIS Spectrum imaging system (Caliper Life
Sciences).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Significance
There are currently no effective therapies for GBM, the most frequent and aggressive
brain tumor. Our results suggest that targeting BUB1B’s GLEBs domain activity may
provide a therapeutic window for GBM, since the GLEBs domain is non-essential in
untransformed cells. Moreover, the results further suggest that sister KT distances at
metaphase may predict sensitivity to anti-cancer therapeutics targeting KT function.
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Figure 1. Integration of RNAi screens in patient-derived BTICs and GBM bionetworks
(A) Overview of shRNA screens, GBM network generation, and results of seeding screen
hits into GBM network (see Methods and Supplementary Information for further details on
GBM network construction and screen comparisons).
(B) BUB1B subnetworks from GBM tumors and also from normal brain networks. Also
indicated are the node inhibition BTIC and NSC growth phenotypes.
(C) Down steam node analysis, a metric that helps predict the relative importance of nodes
(14, 23) of BTIC-specific screen hits which appear in the GBM Bayesian network.
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Figure 2. BUB1B validates as a candidate GBM-lethal gene in vitro
(A) BTIC-specific effects of BUB1B knockdown, visualized using shRNA-GFP+ BTICs
and NSCs 6 days after post-transduction with pGIPz-shRNA virus. Knockdown of KIF11/
EG5, which encodes a microtubule motor protein critical for bi-polar spindle formation
during mitosis, was used as a positive control for both RNAi pathway activity and cell
proliferation.
(B–C) Examination of BUB1B knockdown by western blot and RT-qPCR analysis in BTIC-
G166 and NSC-CB660 cells.
(D) Comparison of the effects of BUB1B knockdown on in vitro expansion of multiple
BTIC and NSC lines and normal human astrocytes (NHAs). **indicates student’s t-test p <.
01. See methods for a description of how BTIC isolates were developmentally subtyped.
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(E) Limiting dilution assays (LDA) for in vitro tumor sphere formation. BTIC-0131 cells
and also un-passaged primary GBM tumor cells (448T) were transduced with indicated LV-
GFP-shRNAs, diluted and assayed for sphere formation after 14 days. Linear regression
analysis was used to evaluate significance.
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Figure 3. Measurement of inter-kinetochore distance (IKD) in BUB1B resistant and sensitive
cells
(A) Cartoon showing IKD measurement.
(B) Measurement of IKDs in BTICs, NSCs, MEF, MEF-Ras, RPE and Hela cells using
immunofluorescent staining of kinetochores. Constitutive associated centromere network
(CCAN/CREST) proteins (red) and outer kinetochore protein, Hec1, (green) were visualized
to identify kinetochore pairs. IKDs were measured between Hec1 centroids using Applied
Precision Softworx software package.
(C–D) Quantification of IKDs from (B). *denotes p<.001 by student’s t-test.
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Figure 4. BTICs with short inter-kinetchore distances require BUB1B activity to suppress KT-
MT attachment defects
(A) Chromosome alignment assays in BTICs and NSCs with BUB1B knockdown.
Transduced cells were treated by 10 μM MG-132 for 2 hours to arrest them at metaphase
and then fixed, stained as indicated (CREST anti-serum stains human kinetochores) and
visualized using deconvolution microscopy. Scale bar indicates 10 microns.
(B) Quantification of misaligned kinetochores (“n” indicates number of metaphase cells
counted; ** indicates p<.001 by student’s t-test).
(C) Chromosome segregation defects observed in BTICs are exacerbated by BUB1B
knockdown. Cells were transduced with LV-GFP-shRNA vectors, selected in puromycin,
stained with an MPM-2 antibody, which marks mitotic cells, and DAPI, and examined for
the appearance of lagging chromosomes in anaphase/telophase cells (n=3, >40 anaphases
scored).
(D) Assays for lagging anaphase chromosomes were performed by overnight arrest with the
KIF11 inhibitor monastrol (100 μM) followed by release for 2 hours in normal media.
Lagging chromosomes were visualized by fluorescence microscopy after fixation and DAPI
staining. White arrows in left panels show typical examples of lagging chromosomes scored
in BTICs (scale bar = 10 μm). >400 nuclei were counted for each trial (n=5).
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Figure 5. Allelic complementation studies with mouse Bub1b mutants in Bub1b−/− MEFs and
BTICs
(A) The mouse alleles used in these studies were previously published and include: full
length; KD2, which harbors two point mutations in the kinase domain (K784>R in the ATP
binding domain and K802>R in the catalytic domain); ΔN, which lacks the N-terminal
Cdc20-binding domain 1; ΔM, which lacks the C-terminal Cdc20-binding domain 2; and
E406K, which creates a point mutation in the GLEBS motif that interferes with kinetochore
localization and Bub3 binding.
(B) Viability assessment of complementation studies using p53−/− MEFs with floxed alleles
of Bub1b with and without transformation via H-RasV12.
Knockdown of BUB1B in Ras-transformed normal human astrocytes (NHAs) phenocopies
BUB1B requirement observed in BTICs with respect to viability. MEFs were transduced
with MSCV-GFP-mBub1b constructs, sorted for GFP+, outgrown, transduced with
pMSCV-Puro-Cre, selected, and seeded into microtiter growth dishes for proliferation
assays.
(C) Viability assessment of complementation studies using BTIC-G166 with shBUB1B (or
controls) expressing each of five mBub1b alleles from (A). Assays were performed as in
Figure 1C.
(D) & (E) Chromosome alignment after complementation of BUB1B knockdown with
mBub1b alleles, as in Figure 4A & 4B. Scale bar indicates 10 microns.
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Figure 6. BUB1B knockdown inhibits BTIC-dependent tumor growth
(A) Orthotopic xenotransplants of 131 BTIC cells after stable transduction with shControl or
shBUB1B. Upper & lower panels: experimental NSG mice 4 and 7 weeks post injection,
respectively. Right panels: light images of brains from control Middle panels: GFP+
fluorescence marking shRNA containing cells. Left panels: fluorescent signal from
Chlorotoxin: Cy5.5 conjugate marking bulk tumor mass. Results indicate that GFP
expressing shBUB1B cells were unable to contribute to formation of orthotopic tumors and
yielded tumor masses dominated by wild type control cells with little to no detectible GFP
expression. Quantification of GFP fluorescence in tumor 0131 orthotopic xenotransplants is
shown in Figure S9.
(B) Survival plots for mice with BTIC-0131 brain xenografts with or without knockdown of
BUB1B. (Median survival for shCtrl = 178 days; shCtrl n=7; shBUB1B n=6)
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Figure 7.
A model for BUB1B function in GBM and genetically transformed cells
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